Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury.

Norman BH, Fisher MJ, Schiffler MA, Kuklish SL, Hughes NE, Czeskis BA, Cassidy KC, Abraham TL, Alberts JJ, Luffer-Atlas D.

J Med Chem. 2018 Mar 8;61(5):2041-2051. doi: 10.1021/acs.jmedchem.7b01806. Epub 2018 Feb 15.

PMID:
29425457
2.

Qualitative and quantitative prediction of human in vivo metabolic pathways in a human hepatocyte-murine stromal cell co-culture model.

Cassidy KC, Yi P.

Xenobiotica. 2018 Dec;48(12):1192-1205. doi: 10.1080/00498254.2017.1395927. Epub 2017 Nov 16.

PMID:
29143555
3.

Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics.

Cassidy KC, Gueorguieva I, Miles C, Rehmel J, Yi P, Ehlhardt WJ.

Xenobiotica. 2018 Apr;48(4):382-399. doi: 10.1080/00498254.2017.1323137. Epub 2017 May 16. Erratum in: Xenobiotica. 2018 Apr;48(4):x-xi.

PMID:
28436712
4.

Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats.

Zhou X, Rougée LR, Bedwell DW, Cramer JW, Mohutsky MA, Calvert NA, Moulton RD, Cassidy KC, Yumibe NP, Adams LA, Ruterbories KJ.

Drug Metab Dispos. 2016 Aug;44(8):1184-92. doi: 10.1124/dmd.116.070623. Epub 2016 May 23.

PMID:
27217490
5.

Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.

Jadhav PK, Schiffler MA, Gavardinas K, Kim EJ, Matthews DP, Staszak MA, Coffey DS, Shaw BW, Cassidy KC, Brier RA, Zhang Y, Christie RM, Matter WF, Qing K, Durbin JD, Wang Y, Deng GG.

ACS Med Chem Lett. 2014 Aug 27;5(10):1138-42. doi: 10.1021/ml500283g. eCollection 2014 Oct 9.

6.

Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors.

Wickremsinhe ER, Hynes SM, Palmieri MD, Mitchell MI, Abraham TL, Rehmel JF, Chana E, Jost LM, Cassidy KC.

Xenobiotica. 2014 Sep;44(9):827-41. doi: 10.3109/00498254.2014.900589. Epub 2014 Mar 26.

PMID:
24666335
7.

Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.

Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, Kulanthaivel P, Jackson KA, Chow KH, McCann DJ, Hu H, Anderson S, Furr NA, Barbuch RJ, Cassidy KC.

Drug Metab Dispos. 2013 Apr;41(4):714-26. doi: 10.1124/dmd.112.048488. Epub 2013 Jan 10.

PMID:
23305709
8.

Preclinical characterization of 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic acid metabolism: in vitro species comparison and in vivo disposition in rats.

Perkins EJ, Cramer JW, Farid NA, Gadberry MG, Jackson DA, Mattiuz EL, O'Bannon DD, Weiss HJ, Wheeler WJ, Wood PG, Cassidy KC.

Drug Metab Dispos. 2003 Nov;31(11):1382-90.

PMID:
14570771
9.
10.

Supplemental Content

Loading ...
Support Center